AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25195371
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Qianlongtong Capsule (1.5 capsules once, tid for 7 days)
Trial: 15801915
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg continuous treatment (once daily)
Trial: 12451189
Drug: IFNbeta‐1a 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 30 micro g IM once weekly
Trial: 12451189
Drug: IFNbeta‐1a 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 60 micro g IM once weekly
Trial: 11019837
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell dose >=2 x 10(6)/kg
Trial: 9260226
Drug: Ferric sulfate
RxNorm normalized name: Ferric Sulfate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric sulfate (FS) solution for 15 sec, rinsed, and covered by zinc oxide‐eugenol paste (ZOE)
Trial: 3549399
Drug: New trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New trivalent vaccine produced exclusively on human tissue
Trial: 3549399
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available M-M-R-II vaccine produced by MSD
Trial: 23051991
Drug: NA-1 (Tat-NR2B9c)
RxNorm normalized name: sodium 1-naphthalenesulfonate
DrugBank: Nerinetide (DB12595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-1 (Tat-NR2B9c) intravenous infusion
Trial: 18705272
Drug: 50mg diacerein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg diacerein tablets administered twice daily for 12 weeks
Trial: 20345617
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL saline)
Trial: 31791333
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D fortified foods (30 μg vitamin D3/day through fortified yoghurt, cheese, eggs, and crisp-bread)
Trial: 16870959
Drug: Concomitant psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant psychotropic medications (82% of patients)
Trial: 16870959
Drug: Symptoms likely
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptoms likely targets of polypharmacy (e.g., depression)
Trial: 12600855
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg Cu/L water
Trial: 12600855
Drug: <0.01 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <0.01 mg Cu/L water
Trial: 10953652
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with continuous positive airway pressure (CPAP)
Trial: 26916657
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (1.5 ml/s)
Trial: 26916657
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (2.0 ml/s)
Trial: 26916657
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (3.0 ml/s)
Trial: 25318111
Drug: Long duration
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long duration of intravenous (IV) antibiotics (125 hours)
Trial: 25318111
Drug: Shorter duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter duration of IV antibiotics (62 hours)
Trial: 25318111
Drug: Transition to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition to oral antibiotics
Trial: 22233325
Drug: Base-in prism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base-in prism treatment
Trial: 19578229
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg single dose (n=91)
Trial: 19578229
Drug: Ciprofloxacin 20
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 20 mg/kg single dose (n=89)
Trial: 12806460
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin (various doses for one day)
Trial: 12806460
Drug: Primaquine (30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (30mg daily for 7 days)
Trial: 12806460
Drug: Primaquine (30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (30mg daily for 5 days)
Trial: 12806460
Drug: Chloroquine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (single dose)
Trial: 2002231
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base 250 mg b.i.d. for 18 months
Trial: 6405417
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg) taken at bedtime
Trial: 25270275
Drug: Lower hemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower hemoglobin threshold (transfusion at 7 g/dL or less)
Trial: 25270275
Drug: Higher hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hemoglobin threshold (transfusion at 9 g/dL or less)
Trial: 20623992
Drug: Panitumumab plus
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab plus chemotherapy (intravenous panitumumab 6 mg/kg every 2 weeks)
Trial: 20623992
Drug: Panitumumab plus
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab plus oxaliplatin-based chemotherapy (FOLFOX4)
Trial: 20623992
Drug: Panitumumab plus
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab plus irinotecan-based chemotherapy (FOLFIRI)
Trial: 20623992
Drug: Panitumumab monotherapy
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab monotherapy plus best supportive care
Trial: 16152826
Drug: Ganshao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganshao Capsule (GSC) for 8 weeks
Trial: 16152826
Drug: Ganshao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganshao Capsule (GSC) followed by Clomiphene (CC) for ovulation induction
Trial: 16152826
Drug: Clomiphene (CC)
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene (CC) for ovulation induction after GSC
Trial: 14660449
Drug: Single drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drop of 2.5% povidone‐iodine ophthalmic solution at birth
Trial: 14660449
Drug: Double drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double drop of 2.5% povidone‐iodine ophthalmic solution (one at birth, one at discharge)
Trial: 10664920
Drug: Repaglinide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (4 mg single dose)
Trial: 9204351
Drug: iopromide 300
RxNorm normalized name: IOPROMIDE 300mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 300 mg I/ml
Trial: 31016447
Drug: iopromide 370
RxNorm normalized name: IOPROMIDE 370mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 370 mg I/ml
Trial: 8995474
Drug: iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 400 mg I/ml
Trial: 28366039
Drug: OTC 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC 1% colloidal oatmeal cream
Trial: 28366039
Drug: Prescription barrier
RxNorm normalized name: BARRIER
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription barrier cream
Trial: 22963270
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (twice a week at 30 minutes/session for 8 weeks)
Trial: 20084934
Drug: Galvanism penetration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galvanism penetration of traditional Chinese medicine, ultrasonic wave and manipulation
Trial: 8390288
Drug: Tc‐99m‐labelled BW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m‐labelled BW 431/26 intact antibody
Trial: 29748010
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + pelareorep (4.5 × 10^10 TCID50, days 1-3 every 21 days)
Trial: 29748010
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (pemetrexed [500 mg/m2, non-squamous] or docetaxel [75 mg/m2], day 1 every 21 days)
Trial: 27240903
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Trial: 27240903
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Trial: 27240903
Drug: 6 or
RxNorm normalized name: Serc-16 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 or 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Trial: 27240903
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Trial: 19941345
Drug: Median compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median compound muscle action potential (CMAP) amplitude and median motor latency
Trial: 18285606
Drug: Targeted anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted anticancer agents (various agents, specific dosages and durations not provided)
Trial: 15678039
Drug: Peak creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak creatine kinase MB level < 25 ng/mL
Trial: 15678039
Drug: Peak creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak creatine kinase MB level ≥ 100 ng/mL
Trial: 10385364
Drug: Splenectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splenectomy with immunotherapy in patients with high IAP levels (>580 microg/ml)
Trial: 10385364
Drug: Preservation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservation of the spleen with immunotherapy in patients with lower IAP values
Trial: 30787634
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone (T20)
Trial: 30787634
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone (T40)
Trial: 30787634
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylprednisolone (M20)
Trial: 30787634
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone (M40)
Trial: 7970954
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine (Group A, 6 units)
Trial: 7970954
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine (Group B, 13 units)
Trial: 7970954
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine (Group C, 25 units)
Trial: 11563435
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment for pathologic gambling disorder (PGD) in geriatric patients
Trial: 11563435
Drug: Nonpharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatment
Trial: 29378708
Drug: Plazomicin 15
RxNorm normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plazomicin 15 mg/kg
Trial: 30248987
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate (25 g of crude protein)
Trial: 30248987
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (25 g of crude protein)
Trial: 30248987
Drug: Insect protein
RxNorm normalized name: Insect protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insect protein isolate (25 g of crude protein)
Trial: 24824991
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment using the Lidcombe Program
Trial: 24824991
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment using the Lidcombe Program
Trial: 22258267
Drug: Oral liquid
RxNorm normalized name: ACAI ORAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid and perceived gastric liquid preloads
Trial: 17632215
Drug: Chlorpromazine (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (200-800 mg/d)
Trial: 12392239
Drug: Deep acupuncture
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep acupuncture treatment
Trial: 12392239
Drug: Superficial (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial (placebo) acupuncture treatment
Trial: 2268811
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of cefazolin
Trial: 2268811
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of cefazolin and three doses of placebo
Trial: 31689865
Drug: Contact needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact needle therapy (CNT) added to usual care
Trial: 26503139
Drug: Girls First
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Girls First (combination of Girls First Resilience Curriculum and Girls First Health Curriculum)
Trial: 11133627
Drug: Clonidine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 150 microg (=1 mL) of clonidine, completed by 1 mL of 0.9% saline IM.
Trial: 11133627
Drug: Control (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 1 mL of 0.9% saline, completed by 150 microg (=1 mL) of clonidine IM.
Trial: 11133627
Drug: Placebo (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine (1/200000) and 1 mL of 0.9% saline, completed by 1 mL of 0.9% saline IM in the controlateral shoulder.
Trial: 2525470
Drug: Fenretinide (HPR)
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (HPR) 300 mg daily for 6 months
Trial: 2525470
Drug: Fenretinide (HPR)
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (HPR) 200 mg daily for 6 months, then 200 mg for another 6 months
Trial: 26670370
Drug: Levothyroxine capsules
RxNorm normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine capsules with esomeprazole (80 mg)
Trial: 26670370
Drug: Levothyroxine tablets
RxNorm normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine tablets with esomeprazole (80 mg)
Trial: 26670370
Drug: Levothyroxine capsules
RxNorm normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine capsules after esomeprazole administration
Trial: 26670370
Drug: Levothyroxine tablets
RxNorm normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine tablets after esomeprazole administration
Trial: 26670370
Drug: Levothyroxine capsules
RxNorm normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine capsules without esomeprazole
Trial: 26670370
Drug: Levothyroxine tablets
RxNorm normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine tablets without esomeprazole
Trial: 21820424
Drug: Propylthiouracil (PTU)
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU) treatment for 6 weeks and 12 weeks
Trial: 18500081
Drug: Cyclosporine 0.05%
RxNorm normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 0.05% drops twice daily for 3 months
Trial: 18500081
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard postoperative LASIK medication)
Trial: 16990383
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aspiration or sham injection)
Trial: 15160543
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 2% lignocaine hydrochloride gel at 4 degrees C
Trial: 15160543
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 2% lignocaine hydrochloride gel at 22 degrees C
Trial: 8020031
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (INR = 1.5-2.7)
Trial: 8020031
Drug: Aspirin, 325
RxNorm normalized name: Aspirin, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 325 mg/day
Trial: 8020031
Drug: Aspirin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 75 mg/day
Trial: 8020031
Drug: Indobufene, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufene, 100 mg bid
Trial: 8020031
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or indobufene or nothing
Trial: 3963031
Drug: Alcohol with
RxNorm normalized name: GNP 70% Isopropyl Alcohol with Wintergreen Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol with drug treatment
Trial: 31299766
Drug: Abobotulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abobotulinum toxin‐A injection (Group 1, n=20)
Trial: 27583688
Drug: Vandetanib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (100 mg daily) with platinum (cisplatin or carboplatin) and etoposide
Trial: 26374703
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg once daily, increased to 200 mg at two weeks)
Trial: 19785978
Drug: Drug court
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug court as usual
Trial: 17195727
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (UCPP and CU)
Trial: 12855087
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality distraction intervention during chemotherapy treatment
Trial: 12855087
Drug: No distraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No distraction intervention (control condition) during alternate chemotherapy treatment
Trial: 8637514
Drug: TNFR:Fc (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc (0.15 mg/kg)
Trial: 8637514
Drug: TNFR:Fc (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc (0.45 mg/kg)
Trial: 8637514
Drug: TNFR:Fc (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc (1.5 mg/kg)
Trial: 1888816
Drug: Renzapride (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renzapride (0.5, 1.0, or 2.0 mg)
Trial: 29684391
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg twice daily for 7 days preoperatively
Trial: 12568832
Drug: Oral E2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2, 1 mg
Trial: 12568832
Drug: Oral E2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2, 1 mg plus gestodene, 25 microg
Trial: 12568832
Drug: Transdermal 17beta‐E2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐E2, 50 microg
Trial: 11007679
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) - anaritide, 0.2 microgram/kg/min, 24-hour infusion
Trial: 6695841
Drug: Medium and
RxNorm normalized name: blood pressure test kit medium and large cuffs MISCELL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium and large meals (greater than or equal to 35% of daily energy needs)